Yahoo! Inc. (NASDAQ:YHOO), the internet media company, agreed to acquire BrightRoll Inc., a programmatic video advertising platform, for $640 million in cash. The deal will combine Yahoo's desktop and mobile video advertising inventory with BrightRoll's programmatic video platform and publisher relationships to bring "substantial value' to advertisers on both platforms. Yahoo! Inc. (NASDAQ:YHOO) said it anticipates the purchase to enhance its EBITDA as BrightRoll's net revenue is expected to exceed $100 million this year. Yahoo said San Francisco, California based BrighRoll powers digital video advertising for the world's largest brands, including 87 of the top 100 U.S. advertisers and 18 of the top 20 advertising technology companies.Click here for a free comprehensive Trend Analysis ReportAmgen, Inc. (NASDAQ:AMGN) and AstraZeneca plc (NYSE:AZN) reported that AMAGINE-3, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1).All key secondary endpoints comparing brodalumab with Stelara and placebo were also met. Results showed that 36.7 percent of patients in the brodalumab 210 mg group, 27.0 percent of patients in the brodalumab 140 mg group, 18.5 percent of patients in the Stelara group and 0.3 percent of patients in the placebo group achieved total clearance of skin disease (PASI 100). In addition, 85.1 percent of patients in the brodalumab 210 mg group, 69.2 percent of patients in the brodalumab 140 mg group, 69.3 percent of patients in the Stelara group and 6.0 percent of patients in the placebo group achieved PASI 75.Click here for a free comprehensive Trend Analysis ReportAmazon.com, Inc. (NASDAQ:AMZN) sales growth in October was faster than the e-commerce average, while eBay (EBAY) grew more slowly and Google (GOOGL, GOOG) shopping was only in line with the average, according to industry source ChannelAdvisor. ChannelAdvisor, which maintains the online equivalent of same-store sales data for retailers, said Amazon.com, Inc. (NASDAQ:AMZN) October same store sales growth was 32.4%, more than twice the e-commerce baseline growth rate of 15% for the month. eBay's growth came in at 4.4%, considerably below the broader e-commerce rate, according to the ChannelAdvisor data. Google Shopping's online same store sales growth measured 13.7%, close to the e-commerce average.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
